Compare HDB & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HDB | SNY |
|---|---|---|
| Founded | 1994 | 1994 |
| Country | India | France |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.6B | 95.7B |
| IPO Year | 2002 | 2001 |
| Metric | HDB | SNY |
|---|---|---|
| Price | $26.26 | $47.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | $30.30 | ★ $54.92 |
| AVG Volume (30 Days) | ★ 7.5M | 4.2M |
| Earning Date | 10-17-2026 | 10-30-2026 |
| Dividend Yield | 1.55% | ★ 5.00% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $3.68 |
| Revenue Next Year | $15.53 | $6.69 |
| P/E Ratio | $18.92 | ★ $6.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.36 | $39.07 |
| 52 Week High | $37.35 | $50.61 |
| Indicator | HDB | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 72.38 | 67.87 |
| Support Level | $22.83 | $45.95 |
| Resistance Level | $27.69 | $48.78 |
| Average True Range (ATR) | 0.47 | 0.88 |
| MACD | 0.28 | 0.20 |
| Stochastic Oscillator | 93.02 | 79.96 |
HDFC Bank Ltd company engaged in providing a range of banking and financial services including retail banking, wholesale banking and treasury operations. Its segments are Treasury, Retail banking, Wholesale banking, and Other banking Operations. Majority of incomes if from Retail Banking which consists of digital banking segment which represents business by Digital Banking Units (DBUs) of the Bank. The said DBUs serves retail customers through the Bank's digital network and other online channels; and Non-Digital Banking which serves retail customers through the Bank's branch network and other channels. The bank generates majority of income from Domestic market. Its products are Personal Loan, Car Loan, Business Loan, Two Wheeler Loan, Gold Loan, Home Loan, Pre-Verified Properties, etc.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.